Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2007, Vol. 27 Issue (1): 6-10    DOI:
    
Generation of the Antibody against the schistosoma japonicum antigen Sj22 with genetic immunization
Download: HTML   PDF(0KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  To study the genetic immunization effectiveness, 16 6-week-old female BALB/C mice were immunized with recombinant plasmids with or without CpG adjuvant, and then boosted with the same recombinant plasmids or the recombinant protein of Schistosoma Japonicum antigen Sj22 in four experimental groups. Mice in group A were immunized with 100μg of plasmid pVAX1-sj22. Mice in group B were immunized with 50μg plasmid pVAX1-sj22 and 20μg CpG adjuvant simultaneous. Mice in group C and D were immunized with pcDNA3.1-sj22. All the mice were immunized at the 0, 3rd, and 6th week by i.m. injection and boosted with recombinant Sj22 protein except group D boosted with the plasmid pcDNA3.1-sj22 at the 9th week. Blood was collected at the 0, 9th and 10th week, and the titer of the serum was detected by ELISA, the specificity of the antibody was examined by Western blot. In conclusion, the antiserum specified to Sj22 protein was obtained by genetic immunization. And the study shows that the application of CpG adjuvant can reduce the amount of the plasmid and the DNA prime-boost protein strategy can improve the effectiveness of immunization reaction in genetic immunization.

Key wordsgenetic immunization      antibody      CpG      Schistosoma Japanicum      Sj22     
Received: 11 September 2006      Published: 10 May 2010
Cite this article:

. Generation of the Antibody against the schistosoma japonicum antigen Sj22 with genetic immunization. China Biotechnology, 2007, 27(1): 6-10.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2007/V27/I1/6

[1] CHEN Xiu-yue,ZHOU Wen-feng,HE Qing,SU Bing,ZOU Ya-wen. Preparation, Purification and Identification of Bacteriophage Qβ Virus-like Particles[J]. China Biotechnology, 2021, 41(7): 42-49.
[2] CHEN Wen-jie,MIAO Xian-feng. Domestic Research and Development Status of Antibody-drug Conjugates and Strategic Layout of Key Enterprises[J]. China Biotechnology, 2021, 41(6): 105-110.
[3] XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang. Recent Progress in Drug Development against COVID-19[J]. China Biotechnology, 2021, 41(6): 111-118.
[4] YUAN Bo,WANG Jie-wen,KANG Guang-bo,HUANG He. Research Progress and Application of Bispecific Nanobody[J]. China Biotechnology, 2021, 41(2/3): 78-88.
[5] MAO Kai-yun,LI Rong,LI Dan-dan,ZHAO Ruo-chun,FAN Yue-lei,JIANG Hong-bo. Analysis of the Current Status of Global Bispecific Antibody Development[J]. China Biotechnology, 2021, 41(11): 110-118.
[6] ZHAO Yan-shu,ZHANG Jin-hua,SONG Hao. Advances in Production of Monoclonal Antibody and Antibody Fragments in Engineered Prokaryotes and Yeast[J]. China Biotechnology, 2020, 40(8): 74-83.
[7] YANG Xiao-ying,LI Meng,ZHAO Wei,TANG Min,ZHANG Zhi-qian. Preparation and Preliminary Characterization of Anti-α2δ1/CD3 Bispecific Antibody[J]. China Biotechnology, 2020, 40(7): 9-14.
[8] WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.
[9] WANG Meng,SONG Hui-ru,CHENG Yu-jie,WANG Yi,YANG Bo,HU Zheng. Accurate Detection of Streptococcus pneumoniae by Using Ribosomal Protein L7 / L12 as Molecular Marker[J]. China Biotechnology, 2020, 40(4): 34-41.
[10] YANG Li,SHI Xiao-yu,LI Wen-lei,LI Jian,XU Han-mei. Optimization of Electroporation Conditions in Construction of Phage Display Antibody Library[J]. China Biotechnology, 2020, 40(4): 42-48.
[11] LI Tong-tong,SONG Cai-ling,YANG Kai-yue,WANG Wen-jing,CHEN Hui-yu,LIU Ming. Preparation and Neutralization Activity of Anti-Canine Parvovirus VP2 Protein Single-chain Antibody[J]. China Biotechnology, 2020, 40(4): 10-16.
[12] CHEN Qiu-li,YANG Li-chao,LI Hui,WEN Sha,LI Gang,HE Min. Prokaryotic Expression,Purification and Preparation of Polyclonal Antibody of Human Nek2 Protein[J]. China Biotechnology, 2020, 40(3): 31-37.
[13] LI Dong-qiao,LV Lu-cheng,YANG Yan-ping. The Research Status and Development Trend of Global Human Coronavirus Antibody Field[J]. China Biotechnology, 2020, 40(1-2): 65-70.
[14] KONG Jian-tao,ZHUANG Ying-ping,GUO Mei-jin. Enhancement of Anti-CD20 Monoclonal Antibody Expression by CHO based on DOE and Amino Acid Supplemental Strategy[J]. China Biotechnology, 2020, 40(12): 41-48.
[15] HE Meng,ZHANG Guo-lin,LI Yan,HAN Xue-bo,LIU Hong-peng,LI Xin,QIAN Ling-ling,LIU Kun-mei,GUO Le. Soluble Expression of Recombinant Antigen CagL from Helicobacter pylori Pathogenicity Island and Preparation and Analysis of Anti-CagA Polyclonal Antibody[J]. China Biotechnology, 2020, 40(11): 21-27.